Research Topics
| D C SmithSummaryAffiliation: University of Michigan Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Secondary hormonal therapyD C Smith
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
Semin Urol Oncol 15:3-12. 1997..In addition, it reviews hormonal agents currently in development that act by other mechanisms to inhibit prostate cancer growth...
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith
University of Michigan, Ann Arbor, MI, USA
J Clin Oncol 31:412-9. 2013..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032David C Smith
University of Michigan, Ann Arbor, Michigan 48109 5948, USA
Urology 77:1172-6. 2011..To assess the efficacy of a multiagent taxane-based chemotherapy combined with hormonal therapy in men with metastatic androgen-dependent prostate cancer in a multicenter, cooperative group, single-arm trial...- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladderDavid C Smith
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
J Urol 180:2384-8; discussion 2388. 2008..This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer... - Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinomaDavid C Smith
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
Cancer 98:269-76. 2003..The authors conducted this clinical trial to evaluate the addition of carboplatin to the three-drug combination of paclitaxel, estramustine, and etoposide (TEE)... - Chemotherapy for hormone refractory prostate cancerD C Smith
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
Urol Clin North Am 26:323-31. 1999..It is hoped that the enrollment of patients into properly designed clinical trials of new agents and combinations will result in the development of therapy with proven efficacy in the near future... - Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancerD C Smith
Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, USA
J Clin Oncol 17:1664-71. 1999..To evaluate the combination of intravenous (IV) paclitaxel, oral estramustine, and oral etoposide in patients with advanced hormone-refractory prostate cancer... - Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancerD C Smith
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
J Clin Oncol 16:1835-43. 1998..Prostate-specific antigen (PSA) has been used as a marker of advanced prostate cancer but remains controversial. To evaluate PSA as a predictor of survival, we analyzed data from sequential phase II trials of estramustine and etoposide... - Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposideH G Munshi
Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Cancer 91:2175-80. 2001..This regimen should not be considered standard therapy for the treatment of early recurrent prostate carcinoma, but further exploration of treatment in this setting is warranted... - Adjuvant and neoadjuvant therapy in prostate cancerC Chay
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
Semin Oncol 28:3-12. 2001..While the use of chemotherapy has been limited by the lack of active agents, newer combinations have shown effectiveness in patients with hormone refractory disease, raising the possibility of their use in the adjuvant setting... - Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinomaB G Redman
Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI, USA
J Clin Oncol 16:1844-8. 1998..Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium... - Phase II trial of suramin in patients with metastatic renal cell carcinomaR Dreicer
Department of Internal Medicine, The University of Iowa, and The University of Iowa Cancer Center, Iowa City, USA
Invest New Drugs 17:183-6. 1999..The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma... - Rapid ("warm") autopsy study for procurement of metastatic prostate cancerM A Rubin
Department of Pathology, University of Michigan, Ann Arbor 48109, USA
Clin Cancer Res 6:1038-45. 2000..The development and expansion of this program represent a valuable resource for molecular and clinical researchers... - Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancerC J McGinn
Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0010, USA
J Clin Oncol 19:4202-8. 2001..The primary objective of this phase I trial was to determine the maximum-tolerated dose of radiation that could be delivered to the primary tumor concurrent with full-dose gemcitabine in patients with advanced pancreatic cancer... - The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminomaJune L Chan
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA
Int J Radiat Oncol Biol Phys 53:934-41. 2002..The purpose of this study was to use utilities to assess the quality of life benefits associated with adjuvant RT in this setting... - Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinomaManish S Bhandari
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
Cancer 106:1715-21. 2006..Its toxicity and activity is similar to that observed when intravenous 5-fluorouracil or capecitabine are given alone. It may be an option for further investigations in combination regimens... - Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostateNiklas J Mackler
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
Cancer 106:2617-23. 2006..More active regimens are needed to further evaluate the utility of this clinical trial design in patients with prostate cancer... - The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplantMerideth M M Wendland
Department of Radiation Oncology, Huntsman Cancer Hospital and the University of Utah, Salt Lake City, Utah 84112, USA
Am J Clin Oncol 30:156-62. 2007..We examined the role of involved field radiation therapy (IFRT) in this setting... - Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain
University of Michigan, Ann Arbor, USA
J Clin Oncol 25:2218-24. 2007.... - Living with prostate cancer: patients' and spouses' psychosocial status and quality of lifeLaurel L Northouse
School of Nursing and the Division of Hematology Oncology, Department of Urology, University of Michigan, Ann Arbor 48109 0482, USA
J Clin Oncol 25:4171-7. 2007..This study assessed patients' and spouses' quality of life, appraisal of illness, resources, symptoms, and risk for distress across three phases of prostate cancer: newly diagnosed, biochemical recurrence, and advanced... - Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancerN Lynn Henry
Department of Internal Medicine, Division of Hematology, University of Michigan School of Medicine, Ann Arbor, Mich, USA
Oncology 71:168-75. 2006..There was no correlation between prostate-specific antigen and levels of angiogenesis factors. CONCLUSIONS: Copper depletion with TM did not delay disease progression in patients with asymptomatic metastatic HRPC... - Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinomaNiklas J Mackler
Department of Internal Medicine, Division of Hematology Oncology University of Michigan Medical School
Clin Genitourin Cancer 5:318-22. 2007..The primary objective of this study was to assess the feasibility and efficacy of administering etoposide/estramustine/paclitaxel in hormone-sensitive metastatic prostate cancer responding to hormonal therapy... - Advances in prostate cancer chemotherapy: a new era beginsKenneth J Pienta
Michigan Urology Center, University of Michigan, Ann Arbor, MI, USA
CA Cancer J Clin 55:300-18; quiz 323-5. 2005..Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development... - Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerMatthew D Galsky
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:1439-46. 2005..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer... - Randomized clinical trial of a family intervention for prostate cancer patients and their spousesLaurel L Northouse
School of Nursing, University of Michigan, Ann Arbor, Michigan 48109 5482, USA
Cancer 110:2809-18. 2007.... - Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategyJoseph M Herman
Department ofRadiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
Urology 64:69-73. 2004..The results of this study suggest that concurrent gemcitabine with conformal RT is a tolerable treatment regimen for bladder preservation, as demonstrated by the excellent treatment compliance and similar FACT measurements... - Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapyWalter J Urba
Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
J Urol 180:2011-7; discussion 2017-8. 2008..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor... - Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: results of a pilot studyPeter C Trask
Behavioral Medicine Program, University of Michigan, MI 48108, USA
Psychooncology 12:814-20. 2003..Deleterious changes in emotional distress, quality of life, and symptom distress seen in other cancer populations were not apparent in our sample of testicular cancer patients... - Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinomaBeth Hellerstedt
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
Cancer 98:1603-10. 2003..CONCLUSIONS: Cyclophosphamide, prednisone, and DES represent a well tolerated, low-cost combination therapy with significant activity in the treatment of patients with AIPC... - Novel gemcitabine-containing triplets in the management of urothelial cancerMaha Hussain
Division of Hematology/Oncology, Wayne State University and the Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
Semin Oncol 29:20-4. 2002..The role of gemcitabine-based multiagent combinations compared with standard therapy awaits evaluation in prospectively randomized trials... - Chemotherapy for localized, high-risk prostate cancerSamir Narayan
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI 48109-0010, USA
Semin Radiat Oncol 13:152-7. 2003..The role of chemotherapy in the nonmetastatic prostate, hormone-naïve prostate cancer patient will be discussed... - Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancerMaha Hussain
Division of Hematology/Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
Urology 61:774-80. 2003..This combination is active; however, its efficacy relative to hormonal therapy will require a controlled randomized trial... - Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano
Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
Cancer 113:975-84. 2008..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)... - Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study designDeborah A Bradley
University of Michigan, Ann Arbor, MI 48109 0946, USA
Clin Genitourin Cancer 5:460-3. 2007..The specific hypothesis of this trial is that sunitinib will decrease progression rates in patients with advanced urothelial cancer who have obtained stable disease or better after standard chemotherapy... - Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)Tahir Latif
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH 44195, USA
Invest New Drugs 23:79-84. 2005..Although JM-216 had moderate activity in HRPC when given on daily basis for 5 days, it is associated with significant treatment related toxicities in this patient population... - Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trialElizabeth Kent
Department of Internal Medicine, University of Michigan School of Medicine and Comprehensive Cancer Center, AnnArbor, 48109, USA
J Clin Oncol 22:2540-5. 2004..The MTD of gemcitabine is 27 mg/m(2). There is a high rate of bladder preservation in this selected group of patients... - Combined modality treatment for prostate cancer: role of chemotherapyHoward M Sandler
Department of Radiation Oncology, University of Michigan Medical School, 1500 E. Medical Center Drive, UH B2C490, Ann Arbor, MI 48109-0010, USA
Semin Oncol 30:95-100. 2003..The role of chemotherapy for patients with nonmetastatic, hormone-naive prostate cancer will be discussed... - Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetateKhalid Matin
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 50:179-85. 2002..Profound suppression of the pituitary-adrenal axis was also observed during the administration of megestrol acetate... - Association between Agent Orange and prostate cancer: a pilot case-control studyVeda Nargund Giri
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0946, USA
Urology 63:757-60; discussion 760-1. 2004..Additional study in larger populations is necessary to confirm and to quantify this association more accurately...
Research Grants
- Phase II Trial of Tetrathiomolybdate in Prostate CancerDavid Smith; Fiscal Year: 2002..The levels of these growth factors/cytokines will then be correlated with the degree of copper depletion, PSA level and response to therapy. ..